Given that PET radiotracers are highly clinically translatable, further optimization of ICAM-1-based PET radiotracers is warranted for an effective noninvasive strategy to guide combinational RT in patients with cancer to facilitate precision therapy. The gene discussed is ICAM1; the disease is cancer.